Nadh Variations
Nadh Reports & Case Studies
Youtube Nadh Testimonials
Celebrity Testimonials
get more help the natural way with the help of nadh
Contact us
About us

02-02-1999 Sufferers of Chronic Fatigue Syndrome (CFS) can be heartened by the favorable results of clinical trials of the nutritional supplement Enada NADH for use in the treatment of their debilitating disorder. The outcome of the Enada NADH study has recently been published in the respected medical journal Annals of Allergy, Asthma & Immunology. (Vol. 82, pp. 185-191, Feb.1999). Healthwatch and The CFIDS & FM Health Resource published preliminary results of this study, which was conducted at the prestigious Georgetown University Medical Center in Washington, D.C. This trial marks one of the first times the FDA has approved a nutritional supplement for evaluation as a medical treatment.

Benefits Seen in the Double-blind, Placebo-Controlled Study Twenty-six patients who met The Centers for Disease Control and Prevention’s (CDC) criteria for CFS completed the 12-week double-blind, placebo-controlled study. Double-blind is a scientific term meaning neither the investigating doctors nor the patients knew who was given Enada NADH or the placebo. During weeks one through four, patients received either 10 mg of Enada NADH or a placebo, whereas weeks five through eight were a ‘wash-out’ period during which patients received no active treatment. During weeks nine through twelve, patients’ treatment was switched so they received the alternate treatment – either placebo or Enada NADH – relative to their first four weeks. Laboratory tests were completed at the beginning and end of the study, and symptoms were evaluated based on patients’ response to an extensive questionnaire given prior to the study, as well as at the conclusion of weeks four, eight and twelve.

Eight of the patients showed at least a 10% improvement while taking Enada NADH, as opposed to only two of those taking the placebo. The success rate after only four weeks of Enada NADH treatment was 31% versus only 8% for patients given the placebo. Presented statistically, patients receiving Enada NADH were four times more likely than those taking a placebo to experience a reduction in symptoms. A Longer Open Label Study Yields Greater Results The authors of this published study feel there is cause for optimism as to even potentially greater benefits of Enada NADH, a safe, naturally- occurring antioxidant, in the treatment of CFS. These doctors believe that a longer period of treatment may result in a higher percentage of patients responding favorably. To test this theory, doctors enrolled patients in a longer, open label (as opposed to double-blind, placebo) follow-up study. The Annals of Al-lergy, Asthma & Immunology journal article reports that to date 72% of patients in this open study have reported significant improvement of their symptoms and energy levels. However, Matthew Fitzsimmons, the president of Menuco Corporation, which supplied the patented form of Enada NADH used in the study, recently revealed that up to 80% of patients in the longer (ongoing) study have responded favorably.







Site Map